RATIONALE: Catechol-O-methyltransferase (COMT) is an enzyme involved in the degradation and inactivation of the neurotransmitter dopamine, which is important in mediating drug reward such as nicotine in tobacco smoke. Different COMT alleles encode enzyme whose activity varies from three- to fourfold that may affect dopamine levels and alter subjective effects of nicotine. Recent evidence also suggests that a COMT polymorphism may be especially important in determining an individual's predisposition to developing nicotine dependence. SUBJECTS AND METHODS: We studied the COMT Val108Met polymorphism in a male population of 203 current smokers, 66 former smokers, and 102 non-smokers. The age-adjusted odds ratios were estimated by multiple logistic regression models. RESULTS: The results showed no significant association of the COMT Val108Met with initiation, persistent smoking, or smoking cessation. However, current smokers with the Met allele had significantly higher Fagerstrom Test for Nicotine Dependence scores (7.5 +/- 2.1 vs 6.8 +/- 1.8, p = 0.018) and started smoking significantly earlier (18.4 +/- 4.9 vs 20.1 +/- 5.9 years, p = 0.036). CONCLUSIONS: These results suggest that the COMT Val108Met polymorphism may not influence smoking status in a Chinese male population but may influence the age at which smoking started and smoking severity among smokers. However, the findings must be regarded as preliminary because of the relatively small sample size and marginal associations and should be replicated in a larger cohort.
RATIONALE: Catechol-O-methyltransferase (COMT) is an enzyme involved in the degradation and inactivation of the neurotransmitter dopamine, which is important in mediating drug reward such as nicotine in tobacco smoke. Different COMT alleles encode enzyme whose activity varies from three- to fourfold that may affect dopamine levels and alter subjective effects of nicotine. Recent evidence also suggests that a COMT polymorphism may be especially important in determining an individual's predisposition to developing nicotine dependence. SUBJECTS AND METHODS: We studied the COMT Val108Met polymorphism in a male population of 203 current smokers, 66 former smokers, and 102 non-smokers. The age-adjusted odds ratios were estimated by multiple logistic regression models. RESULTS: The results showed no significant association of the COMT Val108Met with initiation, persistent smoking, or smoking cessation. However, current smokers with the Met allele had significantly higher Fagerstrom Test for Nicotine Dependence scores (7.5 +/- 2.1 vs 6.8 +/- 1.8, p = 0.018) and started smoking significantly earlier (18.4 +/- 4.9 vs 20.1 +/- 5.9 years, p = 0.036). CONCLUSIONS: These results suggest that the COMT Val108Met polymorphism may not influence smoking status in a Chinese male population but may influence the age at which smoking started and smoking severity among smokers. However, the findings must be regarded as preliminary because of the relatively small sample size and marginal associations and should be replicated in a larger cohort.
Authors: H Ishikawa; T Ohtsuki; H Ishiguro; K Yamakawa-Kobayashi; K Endo; Y L Lin; H Yanagi; S Tsuchiya; K Kawata; H Hamaguchi; T Arinami Journal: Cancer Epidemiol Biomarkers Prev Date: 1999-09 Impact factor: 4.254
Authors: Rungnapa Ittiwut; Jennifer B Listman; Chupong Ittiwut; Joseph F Cubells; Roger D Weiss; Kathleen Brady; David Oslin; Lindsay A Farrer; Henry R Kranzler; Joel Gelernter Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2011-06-08 Impact factor: 3.568
Authors: H Bowers; D Smith; S de la Salle; J Choueiry; D Impey; T Philippe; H Dort; A Millar; M Daigle; P R Albert; A Beaudoin; V Knott Journal: Genes Brain Behav Date: 2015-07-15 Impact factor: 3.449
Authors: Marcus R Munafò; Rachel M Freathy; Susan M Ring; Beate St Pourcain; George Davey Smith Journal: Nicotine Tob Res Date: 2010-11-24 Impact factor: 4.244
Authors: Falk W Lohoff; Andrew E Weller; Paul J Bloch; Aleksandra H Nall; Thomas N Ferraro; Kyle M Kampman; Helen M Pettinati; David W Oslin; Charles A Dackis; Charles P O'Brien; Wade H Berrettini Journal: Neuropsychopharmacology Date: 2008-08-13 Impact factor: 7.853
Authors: Meredith S Shiels; Han Yao Huang; Sandra C Hoffman; Yin Yao Shugart; Judy Hoffman Bolton; Elizabeth A Platz; Kathy J Helzlsouer; Anthony J Alberg Journal: Prev Med Date: 2008-04-01 Impact factor: 4.018
Authors: Ananda B Amstadter; Nicole R Nugent; Karestan C Koenen; Kenneth J Ruggiero; Ron Acierno; Sandro Galea; Dean G Kilpatrick; Joel Gelernter Journal: Psychiatry Date: 2009 Impact factor: 2.458